• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受多粘菌素治疗患者的肾毒性患病率:一项对观察性研究进行荟萃分析的系统评价

Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.

作者信息

Oliota Ana F, Penteado Suelem T, Tonin Fernanda S, Fernandez-Llimos Fernando, Sanches Andreia C

机构信息

Center for Medical and Pharmaceutical Sciences, Universidade Estadual do Oeste do Paraná, Cascavel, Brazil.

Postgraduate Program in Pharmaceutical Sciences, Universidade Federal do Paraná, Curitiba, Brazil.

出版信息

Diagn Microbiol Infect Dis. 2019 May;94(1):41-49. doi: 10.1016/j.diagmicrobio.2018.11.008. Epub 2018 Nov 22.

DOI:10.1016/j.diagmicrobio.2018.11.008
PMID:30635223
Abstract

Colistin and polymyxin B are increasingly reintroduced in clinical practice due to the absence of effective antibiotics for the treatment of emerging infections caused by gram-negative bacteria. The synthesis of current evidence on the characteristics of polymyxins, especially regarding nephrotoxicity, is necessary. This study aims to conduct a systematic review and meta-analysis of cohort-type observational studies in order to identify the prevalence of nephrotoxicity in patients treated with either colistin or polymyxin B. PubMed, Scopus, and DOAJ electronic databases were searched, and manual searches were done. Cohort studies evaluating renal damage (nephrotoxicity) in adult patients caused by colistin or polymyxin B were included. Meta-analyses of the prevalence of nephrotoxicity as well as cumulative meta-analysis and meta-regression were conducted. After the systematic searches, 95 cohorts (n = 7911 patients) were included for analysis. The nephrotoxicity prevalence was 26.7% [confidence interval (CI) 95%: 22.8-30.9%] for colistin and 29.8% (CI 23.8-36.7%) for polymyxin B (P = 0.720). The publication year of the studies, the criteria used to classify renal damage, and the nephrotoxicity as primary or secondary outcome showed a significant influence on the adverse event rates.

摘要

由于缺乏治疗革兰氏阴性菌引起的新发感染的有效抗生素,黏菌素和多黏菌素B在临床实践中的使用日益增多。综合现有关于多黏菌素特性,尤其是肾毒性特性的证据很有必要。本研究旨在对队列类型的观察性研究进行系统评价和荟萃分析,以确定接受黏菌素或多黏菌素B治疗的患者中肾毒性的发生率。检索了PubMed、Scopus和DOAJ电子数据库,并进行了手工检索。纳入评估黏菌素或多黏菌素B引起成年患者肾损害(肾毒性)的队列研究。对肾毒性发生率进行荟萃分析,以及累积荟萃分析和荟萃回归分析。经过系统检索,纳入95个队列(n = 7911例患者)进行分析。黏菌素的肾毒性发生率为26.7%[95%置信区间(CI):22.8 - 30.9%],多黏菌素B为29.8%(CI 23.8 - 36.7%)(P = 0.720)。研究的发表年份、用于分类肾损害的标准以及肾毒性作为主要或次要结局对不良事件发生率有显著影响。

相似文献

1
Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.接受多粘菌素治疗患者的肾毒性患病率:一项对观察性研究进行荟萃分析的系统评价
Diagn Microbiol Infect Dis. 2019 May;94(1):41-49. doi: 10.1016/j.diagmicrobio.2018.11.008. Epub 2018 Nov 22.
2
Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.多黏菌素 B 与黏菌素治疗多重耐药革兰氏阴性菌感染患者的疗效比较:一项系统评价和荟萃分析。
Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16.
3
Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.多黏菌素 B 或黏菌素甲磺酸钠治疗患者发生急性肾损伤的危险因素。
Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.
4
Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.多黏菌素诱导的肾毒性及其预测因素:使用急性肾损伤 RIFLE 标准进行的研究的系统评价和荟萃分析。
Pharmacol Res. 2021 Jan;163:105328. doi: 10.1016/j.phrs.2020.105328. Epub 2020 Dec 2.
5
Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.与多黏菌素相比,接受多黏菌素B治疗的囊性纤维化患者和非囊性纤维化患者的肾毒性。
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02329-16. Print 2017 Apr.
6
Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.静脉注射硫酸黏菌素与多黏菌素 B 治疗危重症患者急性肾损伤的真实世界、回顾性队列研究。
Pharmacotherapy. 2024 Aug;44(8):631-641. doi: 10.1002/phar.4601. Epub 2024 Jul 24.
7
Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?多粘菌素的肾毒性:粘菌素甲磺酸钠与多粘菌素B之间有差异吗?
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02319-16. Print 2017 Mar.
8
Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.黏菌素与多黏菌素 B 诱导的肾毒性之战
Int J Antimicrob Agents. 2024 Feb;63(2):107035. doi: 10.1016/j.ijantimicag.2023.107035. Epub 2023 Nov 17.
9
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?黏菌素和多黏菌素B的药代动力学/药效学:我们做到了吗?
Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18.
10
Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).比较使用美国食品和药物管理局不良事件报告系统(FAERS)报告的粘菌素与多粘菌素 B 的不良事件。
Expert Opin Drug Saf. 2021 May;20(5):603-609. doi: 10.1080/14740338.2021.1890024. Epub 2021 Feb 22.

引用本文的文献

1
Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of Gram-negative bacteremia.蒙特卡罗模拟优化多粘菌素B给药方案用于治疗革兰氏阴性菌血症
Front Cell Infect Microbiol. 2025 Feb 26;15:1533177. doi: 10.3389/fcimb.2025.1533177. eCollection 2025.
2
Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Infections: A Multicenter Cohort Study.头孢他啶-阿维巴坦与黏菌素治疗多重耐药感染的多中心队列研究
Pharmaceuticals (Basel). 2025 Jan 16;18(1):108. doi: 10.3390/ph18010108.
3
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.
耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
4
Evaluating the effects of intravenous magnesium sulfate for prevention of colistin induced acute kidney injury: an open-label, placebo-controlled, block randomized clinical trial.评估静脉注射硫酸镁预防黏菌素所致急性肾损伤的效果:一项开放标签、安慰剂对照、区组随机临床试验。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4559-4570. doi: 10.1007/s00210-024-03583-w. Epub 2024 Nov 6.
5
Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.多粘菌素 B 与多粘菌素 E:两种多粘菌素神经毒性和肾毒性作用的比较。
BMC Infect Dis. 2024 Aug 26;24(1):862. doi: 10.1186/s12879-024-09759-2.
6
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢地尔罗治疗严重需氧革兰氏阴性细菌感染:技术评估以提供一种新的订阅式支付模式。
Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511.
7
Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.头孢他啶/阿维巴坦与多粘菌素B治疗耐碳青霉烯类肺炎克雷伯菌感染的疗效比较:一项倾向评分匹配的多中心真实世界研究
Infection. 2025 Feb;53(1):95-106. doi: 10.1007/s15010-024-02324-8. Epub 2024 Jun 17.
8
Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury .将糊精与黏菌素结合可抑制其毒性、细胞摄取及急性肾损伤。
RSC Pharm. 2024 Feb 5;1(1):68-79. doi: 10.1039/d3pm00014a. eCollection 2024 Apr 18.
9
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Infections.耐多药和广泛耐药感染的当前治疗方法
Antibiotics (Basel). 2024 Mar 15;13(3):261. doi: 10.3390/antibiotics13030261.
10
Intrapulmonary and Systemic Pharmacokinetics of Colistin Following Nebulization of Low-Dose Colistimethate Sodium in Patients with Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant .在由耐碳青霉烯类药物引起的呼吸机相关性肺炎患者中,雾化低剂量多粘菌素甲磺酸钠后多粘菌素的肺内和全身药代动力学
Antibiotics (Basel). 2024 Mar 14;13(3):258. doi: 10.3390/antibiotics13030258.